Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;46(7):1305-1306.
doi: 10.1111/ced.14680. Epub 2021 May 10.

Hidradenitis suppurativa in a transgender man

D Ramos-Rodríguez  1 , J Garcias-Ladaria  1 , G Serra Soler  2 , A Martín-Santiago  1
Affiliations
Review

Hidradenitis suppurativa in a transgender man

D Ramos-Rodríguez et al. Clin Exp Dermatol. 2021 Oct.
No abstract available

PubMed Disclaimer

References

    1. Nguyen TV, Damiani G, Orenstein L et al. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021; 35: 50-61.
    1. Alikhan A, Sayed C, Alavi A et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol 2019; 81: 91-101.
    1. Clark AK, Quinonez RL, Saric S, Sivamani RK. Hormonal therapies for hidradenitis suppurativa: review. Dermatol Online J 2017; 23: 13030/qt6383k0n4.
    1. Wierckx K, Van de Peer F, Verhaeghe E et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med 2014; 11: 222-9.
    1. Park JA, Carter EE, Larson AR. Risk factors for acne development in the first 2 years after initiating masculinizing testosterone therapy among transgender men. J Am Acad Dermatol 2019; 81: 617-18.

Substances